Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Our results indicate that PCa family history may be positively associated with PCa in all ERG and PTEN subtypes, suggesting a role of genetic susceptibility in their development.
|
31318977 |
2020 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Multivariable Cox proportional hazard models were used to assess the association of <i>PTEN/ERG</i> status with lethal prostate cancer (defined as metastasis or prostate cancer specific death), adjusting for patient age, race, pathological grade and stage, and surgical margin status.
|
31502941 |
2020 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
We used multivariable Cox regression to examine associations between statins and prostate cancer risk overall, by measures of clinically-significant disease, and by ERG and PTEN status.
|
31754047 |
2020 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Looking for the hidden mutation: Bannayan-Riley-Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A.
|
31062505 |
2019 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The tumors were sequenced for mutations in the TERT promoter and 22 additional cancer-related genes, interestingly; one patient was shown to carry a deleterious intronic variant in PTEN, a tumor suppressor gene coupled to thyroid tumorigenesis and Cowden syndrome.
|
31699114 |
2019 |
Hamartoma Syndrome, Multiple
|
1.000 |
Biomarker
|
disease |
BEFREE |
These tumors showed null immunostaining for PTEN.She was genetically diagnosed with CS.
|
31664961 |
2019 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Intermediate uveitis in a child with phosphatase and tensin homolog gene mutation and Bannayan-Riley-Ruvalcaba syndrome.
|
31603075 |
2019 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We identified one pathogenic variant in PTEN in a patient subsequently confirmed to have a hereditary hamartoma tumor syndrome (Cowden syndrome) and one patient with a pathogenic heterozygous variant in PMS2 that was originally not identified by WES due to low quality reads resulting from pseudogenes.
|
30809968 |
2019 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Here, we conducted a TCA targeted metabolomics study on 511 individuals with CS, CS-like syndrome, or BRRS with various genotypes (PTEN or SDHx, mutant or wild type [WT]) and phenotypes (cancer or ASD) and a series of 187 population controls.
|
31564436 |
2019 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The lesion is associated with PTEN gene mutation, and it is considered to be one of the diagnostic criteria of Cowden's syndrome.
|
30517962 |
2019 |
Hamartoma Syndrome, Multiple
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
A germline PTEN mutation results in multi-organ involvement and is termed Cowden syndrome.
|
31807781 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
In this study, we reported that KDM5C was highly expressed in PCa and CRPC specimens, and the high expression promoted CRPC cell proliferation through repressing phosphatase and tensin homolog (PTEN) gene epigenetically.
|
30921702 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
PTEN is a ubiquitous tumor suppressor that is often decreased in prostate cancer during tumor progression.
|
31213464 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusions:</b> Our results reveal a previously unidentified cooperative role of RUNX2 overexpression and PTEN haploinsufficiency in prostate tumorigenesis, suggesting that the defined RUNX2-CXCR7-AKT axis can be a viable target for effective treatment of PCa.
|
31281490 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
While PTEN inactivation leads to PC, it is not sufficient for metastasis, the loss of PTEN concurrently with the inactivation of both TP53 and RB1 empower lineage plasticity in PC cells, which substantially promotes PC metastasis and the conversion to PC adenocarcinoma to neuroendocrine PC (NEPC), demonstrating the essential function of TP53 and RB1 in the suppression of PCSCs.
|
30934773 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
PTEN (Phosphatase and Tensin Homolog) mutant is the top common mutated genes in prostate cancer, which makes it a promising biomarker in future individualized treatment.
|
31791268 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
PTEN loss was rare among men with GS6 prostate cancer enrolled in AS at Johns Hopkins.
|
30279579 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
Metabolic reprogramming is one of the contributors to PTEN-loss driven prostate cancer.
|
30854061 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
PTEN loss was significantly (P < 0.05) associated with increasing GG, poorly formed glands (74% of total cases with loss vs 49% of intact), and three well-validated unfavorable pathological features: intraductal carcinoma of the prostate (IDC-P) (69% of total cases with loss vs 12% of intact), cribriform Gleason pattern 4 (38% of total cases with loss vs 10% of intact) and stromogenic PCa (23% of total cases with loss vs 6% of intact).
|
31111513 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We surmise that the cumulative impact of factors such as the pre-treatment immune status, PTEN expression, DNA damage repair gene mutations, and the effects of conventionally used treatments on the anti-tumor immune response should be considered in immunotherapy trial design in PCa.
|
30984182 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
The aim of this study has been to analyze the immunohistochemical (IHC) expression of MSH2, MSH6, MLH1, PMS2, ERG, and PTEN and their potential association with the grade group (GG) grading system (WHO 2016) and PSA recurrence in a series of 200 PrCa (PSMAR-Biobank, Barcelona, Spain).
|
31209634 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We have investigated ETV1, ETV4, and ETV5 overexpression, with or without PTEN loss, and their association with grade group (GG), pathological stage, focality, and PSA recurrence in PrCa.
|
31016435 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
We compared immunohistochemical expression for PTEN and ERG on prostate biopsy cores from patients with Grade Group (GG) 1 or GG2 prostate cancer who had undergone systematic biopsy with concurrent targeted biopsy.
|
31075299 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
We assessed the combined value of TFF3 and PTEN in two cohorts: one is managed surgically for localized PCa and the second is managed non-surgically by androgen deprivation therapy for advanced disease.
|
31129769 |
2019 |
Malignant neoplasm of prostate
|
1.000 |
Biomarker
|
disease |
BEFREE |
In PTEN-deficient prostate cancers, AKT signaling may be activated upon suppression of androgen receptor signaling.
|
30773595 |
2019 |